Form 4: Merck Executive Sanat Chattopadhyay Acquires Shares

Merck's Executive VP and President of MMD, Sanat Chattopadhyay, acquired 13,880 shares of common stock from a performance share unit payout.

Summary

• Sanat Chattopadhyay, Executive Vice President and President of Merck's MMD division, acquired 13,880 shares of Merck & Co., Inc. common stock.
• The acquisition occurred on January 26, 2026, at a price of $107.4 per share.
• These shares were distributed as net after-tax shares upon the satisfaction of performance criteria for performance share units (PSUs) granted on March 31, 2023.
• The performance shares were paid out at 94 percent of target awards, including dividends accrued over the three-year performance period ending December 31, 2025.
• Following this transaction, Mr. Chattopadhyay directly owns 13,880 shares of common stock.
• He also indirectly beneficially owns 74,289 shares via the Sanat Chattopadhyay April 2025 Grantor Retained Annuity Trust, 57,622 shares via the Sanat Chattopadhyay August 2025 Grantor Retained Annuity Trust, and 53,417 shares via the Sanat Chattopadhyay February 2025 Grantor Retained Annuity Trust.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as an executive received shares due to meeting performance targets, indicating good company performance and aligning executive interests with shareholders. However, it's a routine compensation event, not a major strategic announcement.

Positives

• An executive received a significant number of shares (13,880) as a result of performance share units meeting their criteria, indicating successful performance over the three-year period.
• The payout included dividends accrued over the performance period, adding to the total value received.
• The executive's direct beneficial ownership in the company increased, aligning management interests with shareholders.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to executive compensation, common across publicly traded companies in the pharmaceutical industry and beyond. It reflects the vesting and payout of previously granted performance-based equity awards.

Comparison to Industry Standards

• Performance share units (PSUs) are a standard component of executive compensation packages in large pharmaceutical companies like Merck, aligning executive incentives with long-term company performance.
• A payout at 94% of target indicates that performance criteria were largely met, which is a common outcome for well-structured incentive plans, often falling within a range of 80-120% of target depending on specific performance against goals.

Related Party Transactions

• The reporting person indirectly beneficially owns shares through three Grantor Retained Annuity Trusts (GRATs) (April 2025, August 2025, February 2025), for which he serves as the sole trustee and maintains complete investment control.

Stakeholder Impact

• Shareholders: Increased direct ownership by a key executive can be viewed positively, as it further aligns management's financial interests with those of the shareholders.
• Employees: The payout of performance-based awards can signal a healthy compensation structure and achievement of company goals, potentially boosting morale.

Key Dates

Keywords

Merck, MRK, Sanat Chattopadhyay, Insider Transaction, Stock Acquisition, Executive Compensation, Performance Share Units, Grantor Retained Annuity Trust